In Vivo Analysis of a Noncoding Susceptibility Region for Coronary Artery Disease

冠状动脉疾病非编码易感区的体内分析

• 批准号: 7932876
• 负责人: Len Alexander Pennacchio
• 金额: $ 42.15万
• 依托单位: UNIVERSITY OF CALIF-LAWRENC BERKELEY LAB
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-09-30 至 2011-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7932876
• 关键词: 9p21; Affect; Alleles; Animal Model; Animals; Aorta; Arterial Fatty Streak; Atherosclerosis; Binding; Binding Sites; Biological Assay; Biological Process; Candidate Disease Gene; Cardiac; Cardiovascular Diseases; Cell Proliferation; Chromatin; Chromosomes, Human, Pair 4; Chromosomes, Human, Pair 9; Clinical; Code; Coronary Arteriosclerosis; Country; Coupled; Cyclin-Dependent Kinase Inhibitor; DNA Sequence; Data; Development; Diet; Disease; Disease susceptibility; Distant; EP300 gene; Enhancers; Epidemiologic Studies; Fatty acid glycerol esters; Gene Expression; Gene Expression Profiling; Genes; Genetic; Genetic Polymorphism; Genetically Engineered Mouse; Genome; Genomics; Genotype; Goals; Haplotypes; Heart; Heart Diseases; Human; Human Chromosomes; Incidence; Individual; Knockout Mice; Laboratories; Lead; Link; Linkage Disequilibrium; Lipids; Liver; Maps; Molecular Profiling; Monitor; Morbidity - disease rate; Mus; Pathway interactions; Phenotype; Plasma; Predisposition; Proteins; Risk; Role; Severities; Smooth Muscle Myocytes; System; Testing; Time; Tissues; Transcript; Transcription Coactivator; Transgenic Mice; Variant; cardiovascular disorder risk; cardiovascular risk factor; chromatin immunoprecipitation; clinical phenotype; clinically relevant; deviant; disorder risk; genome wide association study; genome-wide; human disease; in vivo; mRNA Expression; mortality; mouse genome; mouse model; public health relevance

DESCRIPTION (provided by applicant): Large epidemiological studies have indicated that genetic factors contribute significantly to the development of coronary atherosclerosis, a major cause of morbidity and mortality in Western countries. Through genome-wide association studies (GWASs), we and others have identified a strong link between a 58kb noncoding region on 9p21 and coronary artery disease (CAD). The mechanism by which sequence variation at this locus influences CAD is not known since the interval does not contain any protein-coding genes. To provide an animal model to study this CAD-associated noncoding region, we have deleted the orthologous interval (chr4?70kb) from the mouse genome and show that it significantly impacts on cardiac expression of two genes (Cdkn2a and Cdkn2b) adjacent to the deletion. Accordingly, the central goal of this application is to use this and other genetically engineered mice to uncover the mechanism by which sequence variation in this noncoding interval confers susceptibility to CAD. The specific aims are to (1) identify genes/pathways abnormally expressed in the chr4?70kb mice, (2) to identify and characterize transcriptional enhancers within the deleted interval through a transgenic mouse enhancer assay, (3) to test CAD-associated sequence variants in the enhancers that we have identified in the linkage disequilibrium interval for their impact on gene expression in vivo, and (4) to determine the effect of the chr4?70kb deletion on murine atherosclerosis susceptibility and cellular proliferation. These studies will explore the mechanism of how the human 9p21 linkage disequilibrium region causes CAD susceptibility and serve as a paradigm for relating disease-associated DNA sequence variants occurring in noncoding regions to clinically relevant phenotypes. PUBLIC HEALTH RELEVANCE: Genome-wide association studies (GWASs) have revealed a number of genomic intervals that contribute to human disease but are devoid of protein-coding genes. Remarkably, many individuals have a substantially increased risk for developing coronary artery disease due to sequence variations in a noncoding region of human chromosome 9p21, yet the disease- causing mechanism remains cryptic. Accordingly, we propose to utilize genetically engineered mouse models to study in a controlled laboratory setting how these noncoding sequence changes lead to heart disease in humans.

描述（由申请人提供）：大型流行病学研究表明，遗传因素对冠状动脉粥样硬化的发展有重要作用，这是西方国家发病率和死亡率的主要原因。通过全基因组关联研究（GWASs），我们和其他人已经确定了9 p21上58 kb的非编码区与冠状动脉疾病（CAD）之间的密切联系。该位点的序列变异影响CAD的机制尚不清楚，因为该区间不包含任何蛋白质编码基因。为了提供一个动物模型来研究这个CAD相关的非编码区，我们删除了orthogonal间隔（chr 4？70 kb），并显示其显著影响与缺失相邻的两个基因（Cdkn 2a和Cdkn 2b）的心脏表达。因此，本申请的中心目标是使用这种和其他基因工程小鼠来揭示该非编码区间中的序列变异赋予对CAD的易感性的机制。具体的目的是（1）确定基因/途径异常表达的chr 4？70 kb小鼠，（2）通过转基因小鼠增强子测定确定和表征缺失区间内的转录增强子，（3）测试我们在连锁不平衡区间确定的增强子中CAD相关序列变体对体内基因表达的影响，以及（4）确定chr 4？70 kb缺失对小鼠动脉粥样硬化易感性和细胞增殖的影响。这些研究将探索人类9 p21连锁不平衡区如何导致CAD易感性的机制，并作为将非编码区中发生的疾病相关DNA序列变异与临床相关表型相关联的范例。公共卫生相关性：全基因组关联研究（GWASs）揭示了许多基因组间隔，有助于人类疾病，但缺乏蛋白质编码基因。值得注意的是，由于人类染色体9 p21非编码区的序列变异，许多个体患冠状动脉疾病的风险大大增加，但致病机制仍然是神秘的。因此，我们建议利用基因工程小鼠模型，在受控的实验室环境中研究这些非编码序列的变化如何导致人类心脏病。